地特胰岛素在糖尿病基础-餐时治疗模式中的应用
被引量：1
摘要
糖尿病（DM）是以高血糖为主要特征的慢性进行性疾病。相对或绝对的胰岛素分泌不足是DM的主要病因，因此胰岛素的补充治疗是十分重要的治疗措施之一。从治疗的角度看，为实现血糖控制达标、最大程度地保护残存胰岛B细胞数量、恢复胰岛B细胞功能、缓解DM病情、降低DM并发症及相关心血管风险等目标，较理想的策略是最大程度地利用药物或／和胰岛素模拟生理性胰岛素分泌，即采用基础＋餐时治疗模式。
出处
《药品评价》
CAS
2009年第6期252-255,共4页
Drug Evaluation
参考文献8
-
1Hollander P,Cooper J,Bregnhφj J,et al.A 52-week,multinational,openlabel,parallel-group,noninferiority,treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes[].Clinical Therapeutics.2008
-
2Raskin P.Efficacy and safety of insulin detemir[].Journal of Endocrinology and Metabolism.2007
-
3Yenigun M,Honka M.Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen:results from a subgroup of the PREDICTIVE study[].International Journal of Clinical Practice.2009
-
4Heise T,Pieber TR.Towards peakless,reproducible and long-acting insulins.An assessment of the basal analogues based on isoglycaemic clamp studies[].Diabetes Obesity and Metabolism.2007
-
5Duckworth W,Abraira C,Moritz T,et al.Glucose control andvascular complications in veterans with type 2 diabetes[].The New England Journal of Medicine.2009
-
6L.F. Meneghini,K.H. Rosenberg,C. Koenen.Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE st[].Diabetes Obesity and Metabolism.2007
-
7S. Sreenan,A. Virkamaki,K. Zhang,J.B. Hansen.The PREDICTIVE study group. Switching from NPH insulin to once-daily insulin detemir in basal-bolus treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE study[].International Journal of Clinical Practice.2008
-
8L.F. Meneghini,C. Koenen,W. Wend,J. Selam.The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes - results from the randomized, controlled predictive 303 Study[].Diabetes Obesity and Metabolism.2007
同被引文献6
-
1魏爱生,王甫能,陈苹,郅敏,陈发胜,郎江明.甘精胰岛素联合格列美脲及阿卡波糖治疗2型糖尿病患者24小时动态血糖变化[J].中华内分泌代谢杂志,2006,22(4):325-326. 被引量：104
-
2潘长玉.Joslin糖尿病学.北京:人民卫生出版社,2007:558-559.
-
3陆再英,钟南山.内科学.第7版.北京:人民卫生出版社,2010:483-488.
-
4刘芳,贾伟平.地特胰岛素在基础-OAD方案中的应用[J].药品评价,2009,6(6):248-251. 被引量：1
-
5董瓅瑾,宋光明,丁全福.地特胰岛素药理学研究进展[J].武警医学院学报,2011,20(8):678-681. 被引量：4
-
6李延兵,翁建平,许雯,陈小华,廖志红,姚斌,邓婉萍,欧香忠,胡国亮.短期持续胰岛素输注治疗对初诊2型糖尿病患者胰岛β细胞功能的影响[J].中国糖尿病杂志,2003,11(1):10-15. 被引量：777
-
1陈耀,陈兆樵,王翠珍,邓新宇.人胰岛素治疗2型糖尿病58例临床观察[J].中原医刊,2003,30(4):7-8. 被引量：1
-
2刘女士.胰岛素促泌剂与胰岛素增敏剂有何异同？[J].糖尿病新世界,2007(12):48-48.
-
3崔梅,卢玉宏.正确使用降血糖药物[J].基层医学论坛（B版）,2007,11(4):363-364.
-
4冯晋光.正确选择磺脲类降糖药[J].糖尿病之友,2005(1):63-63.
-
5刘芳,刘满.二甲双胍和格列齐特治疗2型糖尿病临床观察[J].河北医药,2008,30(4):500-501. 被引量：1
-
6吴杏梅.2010年我院口服抗糖尿病药物用药分析[J].实用医技杂志,2011,18(10):1030-1030. 被引量：2
-
7段艳峰.观察门冬胰岛素联合地特胰岛素在妊娠期糖尿病的疗效[J].中国实用医药,2016,11(19):186-187. 被引量：13
-
8医海拾贝[J].中华内科杂志,2011,50(2):143-143.
-
9李承玮,张才华.胰岛素类似物的研究进展[J].中国基层医药,2008,15(9):1569-1570. 被引量：1
-
10陈灿,刘江华,祖旭宇,文格波.胰岛素信号通路与动脉粥样硬化[J].国际病理科学与临床杂志,2013,33(1):62-66. 被引量：9
